These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 26001047)
1. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047 [TBL] [Abstract][Full Text] [Related]
2. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A; Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131 [TBL] [Abstract][Full Text] [Related]
3. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Atanackovic D; Panse J; Hildebrandt Y; Jadczak A; Kobold S; Cao Y; Templin J; Meyer S; Reinhard H; Bartels K; Lajmi N; Zander AR; Marx AH; Bokemeyer C; Kröger N Haematologica; 2011 Oct; 96(10):1512-20. PubMed ID: 21606160 [TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070 [TBL] [Abstract][Full Text] [Related]
5. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ; Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420 [TBL] [Abstract][Full Text] [Related]
6. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187 [TBL] [Abstract][Full Text] [Related]
7. The role of surface molecule CD229 in Multiple Myeloma. Olson M; Radhakrishnan SV; Luetkens T; Atanackovic D Clin Immunol; 2019 Jul; 204():69-73. PubMed ID: 30326256 [TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276 [TBL] [Abstract][Full Text] [Related]
9. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Martín P; Santón A; Bellas C Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904 [TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879 [TBL] [Abstract][Full Text] [Related]
11. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094 [No Abstract] [Full Text] [Related]
12. Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias. Perez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Garcia-Marcos MA; Moreno I; Dominguez M; Galende J; Heras N; Gonzalez MI; San Miguel JF; Orfao A; J Biol Regul Homeost Agents; 2004; 18(2):161-5. PubMed ID: 15471221 [TBL] [Abstract][Full Text] [Related]
13. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Girlanda S; Fortis C; Belloni D; Ferrero E; Ticozzi P; Sciorati C; Tresoldi M; Vicari A; Spies T; Groh V; Caligaris-Cappio F; Ferrarini M Cancer Res; 2005 Aug; 65(16):7502-8. PubMed ID: 16103105 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Tembhare PR; Ghogale S; Tauro W; Badrinath Y; Deshpande N; Kedia S; Cherian K; Patkar NV; Chatterjee G; Gujral S; Subramanian PG Cytometry B Clin Cytom; 2018 May; 94(3):509-519. PubMed ID: 29316178 [TBL] [Abstract][Full Text] [Related]
15. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ; Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149 [TBL] [Abstract][Full Text] [Related]
16. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Radhakrishnan SV; Luetkens T; Scherer SD; Davis P; Vander Mause ER; Olson ML; Yousef S; Panse J; Abdiche Y; Li KD; Miles RR; Matsui W; Welm AL; Atanackovic D Nat Commun; 2020 Feb; 11(1):798. PubMed ID: 32034142 [TBL] [Abstract][Full Text] [Related]
17. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489 [TBL] [Abstract][Full Text] [Related]
18. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038 [TBL] [Abstract][Full Text] [Related]
19. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079 [TBL] [Abstract][Full Text] [Related]
20. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ; Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]